A first-line triplet regimen comprising ipatasertib, an oral ATP-competitive Akt inhibitor, atezolizumab, a programmed death-ligand 1 (PD-L1), and a chemotherapy agent, is currently under investigation in metastatic triple-negative breast cancer [23]. The gene discussed is CD274; the disease is triple-negative breast carcinoma.